Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 24 2023 - 3:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________
FORM 6-K
__________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2023
Commission file number: 001-40231
__________________________
Universe Pharmaceuticals INC
__________________________
265 Jingjiu Avenue
Jinggangshan Economic and Technological Development Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)
__________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
In connection with the 2023 Annual General Meeting of Shareholders of Universe Pharmaceuticals INC, a company incorporated under the laws of the Cayman Islands (the “Company”), the Company hereby furnishes the following documents:
Exhibits
1
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Universe Pharmaceuticals INC.
|
Date: May 24, 2023
|
|
By:
|
|
/s/ Gang Lai
|
|
|
|
|
Gang Lai
|
|
|
|
|
Chief Executive Officer
|
2
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Jan 2024 to Jan 2025